Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
Publication
, Journal Article
Mark, DB; Simons, TA
Published in: Am Heart J
May 1999
Duke Scholars
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
May 1999
Volume
137
Issue
5
Start / End Page
S123 / S125
Location
United States
Related Subject Headings
- United States
- Platelet Aggregation Inhibitors
- Immunoglobulin Fab Fragments
- Humans
- Hospital Costs
- Economics, Pharmaceutical
- Cost-Benefit Analysis
- Cost of Illness
- Clinical Trials as Topic
- Cardiovascular System & Hematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Mark, D. B., & Simons, T. A. (1999). Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. Am Heart J, 137(5), S123–S125. https://doi.org/10.1016/s0002-8703(99)70445-x
Mark, D. B., and T. A. Simons. “Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.” Am Heart J 137, no. 5 (May 1999): S123–25. https://doi.org/10.1016/s0002-8703(99)70445-x.
Mark DB, Simons TA. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. Am Heart J. 1999 May;137(5):S123–5.
Mark, D. B., and T. A. Simons. “Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.” Am Heart J, vol. 137, no. 5, May 1999, pp. S123–25. Pubmed, doi:10.1016/s0002-8703(99)70445-x.
Mark DB, Simons TA. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. Am Heart J. 1999 May;137(5):S123–S125.
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
May 1999
Volume
137
Issue
5
Start / End Page
S123 / S125
Location
United States
Related Subject Headings
- United States
- Platelet Aggregation Inhibitors
- Immunoglobulin Fab Fragments
- Humans
- Hospital Costs
- Economics, Pharmaceutical
- Cost-Benefit Analysis
- Cost of Illness
- Clinical Trials as Topic
- Cardiovascular System & Hematology